Press Releases / Stock Exchange Intimation
| Date | Title | Report |
|---|
| 15 May 2025 | Request for Promoter/ Promoter Group Reclassification |
|
PDF 3.10 MB |
| 15 May 2025 | Arco Lab Demerger – update |
|
PDF 3.10 MB |
| 10 May 2025 | Movement in Senior Management Personnel of the Company |
|
PDF 525 KB |
| 30 Apr 2025 | Strides Strengthens Anti-Inflammatory Portfolio with USFDA Approval for Celecoxib Capsules, 100 mg, 200 mg, and 400 mg |
|
PDF 420 KB |
| 29 Apr 2025 | Strides acquires identified ANDAs from Nostrum Laboratories, Inc., USA |
|
PDF 512 KB |
| 11 Apr 2025 | Incorporation of Step-down Wholly Owned Subsidiary – Pivot Path |
|
PDF 420 KB |
| 03 Apr 2025 | KMPs for determining materiality of events or information and making disclosure to the Stock Exchanges under LODR |
|
PDF 520 KB |
| 01 Apr 2025 | Update on redemption of NCDs |
|
PDF 330 KB |
| 19 Mar 2025 | Update relating to Amexel acquisition |
|
PDF 330 KB |
| 19 Mar 2025 | Proposed de-merger of Identified Business of Arco Lab Private Limited (“Arco Lab”), a Wholly owned Subsidiary of the Company |
|
PDF 330 KB |
| 18 Mar 2025 | Dissolution of Generic Partners, UK |
|
PDF 570 KB |
| 14 Mar 2025 | Acquisition of 100% stake in Amexel Pte. Ltd. |
|
PDF 690 KB |
| 18 Feb 2025 | Newspaper Advertisement - Notice of Postal Ballot dated January 30, 2025 |
|
PDF 9.10 MB |
| 31 Jan 2025 | Newspaper Advertisement- Unaudited Financial Results for the quarter and nine months ended December 31, 2024 |
|
PDF 4.14 MB |
| 30 Jan 2025 | Outcome of Board Meeting – Un-Audited Financial Results (Standalone & Consolidated) for quarter and nine months ended December 31, 2024 |
|
PDF 3.10 MB |
| 30 Jan 2025 | Outcome of Board Meeting – Press Release & Earnings Presentation |
|
PDF 1.42 MB |
| 30 Jan 2025 | Outcome of Board Meeting – Board Changes |
|
PDF 364 KB |
| 30 Jan 2025 | Outcome of Board Meeting –Change in Registered Office of the Company |
|
PDF 271 KB |
| 30 Jan 2025 | Integrated Filing – Financials for the quarter and nine months ended December 31, 2024 |
|
PDF 3.10 MB |
| 24 Jan 2025 | Intimation of Board Meeting scheduled on January 30, 2025 |
|
PDF 244 KB |
| 23 Jan 2025 | OneSource Listing |
|
PDF 443 KB |
| 22 Jan 2025 | Strides Pharma debuts with a stellar ESG rating of 76/100 in the S&P Global’s Corporate Sustainability Assessment (CSA) 2024 |
|
PDF 475 KB |
| 21 Jan 2025 | SE Intimation – Transfer pricing assessment |
|
PDF 267 KB |
| 20 Jan 2025 | Product Approval- Acetaminophen and Ibuprofen |
|
PDF 404 KB |
| Date | Title | Report |
|---|
| 27 Dec 2024 | LOC – Ashok Kumar |
|
PDF 382 KB |
| 04 Dec 2024 | LOC – V Ram Mohan |
|
PDF 362 KB |
| 30 Nov 2024 | Newspaper Advertisement - Notice of Record Date |
|
PDF 2.05 MB |
| 29 Nov 2024 | Voting Results of Postal Ballot pursuant to Reg. 44 of SEBI Listing Regulations |
|
PDF 2.98 MB |
| 29 Nov 2024 | Intimation under Regulation 30 of LODR |
|
PDF 300 KB |
| 29 Nov 2024 | LOC – Leela Rathi |
|
PDF 365 KB |
| 27 Nov 2024 | Intimation of Effective Date for Scheme of Arrangement |
|
PDF 357 KB |
| 26 Nov 2024 | Intimation of Record Date for Scheme of Arrangement |
|
PDF 571 KB |
| 25 Nov 2024 | Update about successful completion of fund raising of USD 95 Million by Onesource |
|
PDF 546 KB |
| 21 Nov 2024 | Appointment of Dr. C Muthulingam – Head of R&D |
|
PDF 2.31 MB |
| 19 Nov 2024 | Receipt of NCLT Approval for creation of OneSource – India’s first Specialty Pharma CDMO |
|
PDF 2.31 MB |
| 14 Nov 2024 | Loss of Share Certificate Intimation – Surekha Jadhav & Pradeep Jadhav |
|
PDF 1.01 MB |
| 05 Nov 2024 | Loss of Share Certificate Intimation - P R Soma Sundaram & Somya Somasundram |
|
PDF 1.19 MB |
| 29 Oct 2024 | LOC – K N Unnikrishnan |
|
PDF 370 KB |
| 25 Oct 2024 | Consolidation of Business in Europe |
|
PDF 598 KB |
| 25 Oct 2024 | Newspaper Advertisement- Unaudited Financial Results for the quarter and half year ended September 30, 2024 |
|
PDF 1.16 MB |
| 24 Oct 2024 | Loss of Share Certificate Intimation - M Premachandran Nair & Seema Nair |
|
PDF 1.01 MB |
| 24 Oct 2024 | Outcome of Board Meeting – Un-Audited Financial Results (Standalone & Consolidated) for quarter and half year ended September 30, 2024 |
|
PDF 724 KB |
| 24 Oct 2024 | Outcome of Board Meeting – Press Release & Earnings Presentation |
|
PDF 1.42 MB |
| 24 Oct 2024 | Outcome of Board Meeting - Investment in AMPIN for captive consumption of Solar Energy |
|
PDF 286 KB |
| 24 Oct 2024 | Outcome of Board Meeting – Re-appointment of Dr. Kausalya Santhanam (DIN: 06999168) as Independent Director of the Company |
|
PDF 388 KB |
| 23 Oct 2024 | Loss of Share Certificate Intimation - Thankamony Joe & Joe Thomas |
|
PDF 1.01 MB |
| 23 Oct 2024 | LOC - Rajagopalan J |
|
PDF 351 KB |
| 17 Oct 2024 | Loss of Share Certificate Intimation |
|
PDF 1.05 MB |
| 16 Oct 2024 | OneSource, the Group’s Spec Pharm CDMO, receives equity commitments of INR 8,010 mn (USD 95 mn) from marquee investors at a pre-money equity valuation of USD 1.65 bn |
|
PDF 583 KB |
| 09 Oct 2024 | Loss of Share Certificate Intimation |
|
PDF 1.05 MB |
| 09 Oct 2024 | Intimation under Reg 30 of SEBI LODR – Newspaper advertisement |
|
PDF 3.31 MB |
| 08 Oct 2024 | Strides’ Sustainability Report for FY24 |
|
PDF 9.51 MB |
| 07 Oct 2024 | Loss of share certificate intimation - Krishnan P S and Geetha Krishnan |
|
PDF 1.13 MB |
| 01 Oct 2024 | Intimation under Regulation 30 of SEBI LODR |
|
PDF 223 KB |
| 27 Sep 2024 | Loss of share certificate intimation – K Dhana Lakshmi |
|
PDF 614 KB |
| 27 Sep 2024 | Outcome of 33rd Annual General Meeting of the Company |
|
PDF 902 KB |
| 26 Sep 2024 | Corporate Deck of OneSource |
|
PDF 3.51 MB |
| 25 Sep 2024 | Intimation under Regulation 30 of SEBI LODR |
|
PDF 440 KB |
| 17 Sep 2024 | Intimation regarding receipt of Order from Reserve Bank of India, Foreign Exchange Department, Mumbai. |
|
PDF 544 KB |
| 16 Sep 2024 | Strides receives USFDA approval for Fluoxetine Tabs 60 mg; Expanding the Product’s Availability Across Strengths |
|
PDF 432 KB |
| 12 Sep 2024 | Update on Scheme of Amalgamation of Strides Alathur Private Limited (formerly known as Vivimed Life Sciences Private Limited) into the Company. |
|
PDF 227 KB |
| 11 Sep 2024 | Press Release - Approval from Equity Shareholders and Secured Creditors |
|
PDF 513 KB |
| 11 Sep 2024 | Voting Results - NCLT Convened Meetings – Sept 11, 2024 |
|
PDF 6.75 MB |
| 10 Sep 2024 | Proceedings of NCLT Convened Meetings – Sept 10, 2024 |
|
PDF 630 KB |
| 06 Sep 2024 | Intimation under Regulation 30 of SEBI LODR |
|
PDF 216 KB |
| 06 Sep 2024 | Strides receive USFDA approval for Theophylline Extended-Release Tablets, 300 mg and 450 mg |
|
PDF 463 KB |
| 02 Sep 2024 | Notice of the 33rd Annual General Meeting and Annual Report for FY 2023-24 |
|
PDF 6.81 MB |
| 28 Aug 2024 | Intimation under Regulation 30 of SEBI LODR |
|
PDF 325 KB |
| 22 Aug 2024 | Intimation pursuant to Regulation 31A |
|
PDF 378 KB |
| 22 Aug 2024 | AGM_Intimation of Record Date |
|
PDF 286 KB |
| 19 Aug 2024 | EIR from USFDA on continued GMP status for the facility in Alathur, Chennai |
|
PDF 211 KB |
| 14 Aug 2024 | Intimation under Regulation 30 of SEBI LODR |
|
PDF 333 KB |
| 14 Aug 2024 | Pronouncement of Order by NCLT regarding Scheme of Amalgamation of Strides Alathur |
|
PDF 268 KB |
| 09 Aug 2024 | Notice of meetings - Eq shareholders and Secured Creditors |
|
PDF 548 KB |
| 09 Aug 2024 | Intimation under Reg 30 of SEBI LODR – Newspaper advertisement |
|
PDF 6.78 MB |
| 05 Aug 2024 | Acquisition of balance stake in Strides Global Consumer Healthcare Limited, UK |
|
PDF 310 KB |
| 30 Jul 2024 | Intimation under Regulation 30 of SEBI LODR |
|
PDF 269 KB |
| 30 Jul 2024 | Update on Scheme of Arrangement amongst Strides Pharma Science Limited and Steriscience Specialties Private Limited and Onesource Specialty Pharma Limited (formerly known as Stelis Biopharma Limited) and their respective shareholders, under Section 230 to 232 of the Companies Act, 2013. |
|
PDF 290 KB |
| 30 Jul 2024 | Newspaper Advertisement-Unaudited Financial Results for the quarter ended June 30, 2024 |
|
PDF 1.00 MB |
| 29 Jul 2024 | Voting Results of Postal Ballot pursuant to Reg. 44 of SEBI Listing Regulations |
|
PDF 1.89 MB |
| 29 Jul 2024 | Outcome of Board Meeting – Un-Audited Financial Results (Standalone & Consolidated) for quarter ended June 30, 2024 |
|
PDF 634 KB |
| 29 Jul 2024 | Outcome of Board Meeting – Press Release & Earnings Presentation |
|
PDF 1.29 MB |
| 29 Jul 2024 | Outcome of Board Meeting - Allotment of Shares |
|
PDF 289 KB |
| 29 Jul 2024 | Outcome of Board Meeting - Intimation pursuant to Board approval for Promoter Reclassification |
|
PDF 555 KB |
| 27 Jul 2024 | Incorporation of Step-down Wholly Owned Subsidiary in New Zealand |
|
PDF 304 KB |
| 26 Jul 2024 | Loss of share certificate intimation |
|
PDF 362 KB |
| 24 Jul 2024 | Request for Promoter/ Promoter Group Reclassification |
|
PDF 786 KB |
| 23 Jul 2024 | Intimation under Reg 39 (3) of LODR – Leela Tathi |
|
PDF 329 KB |
| 16 Jul 2024 | Intimation under Reg 39 (3) of LODR – Sriram Shankar |
|
PDF 333 KB |
| 27 Jun 2024 | Newspaper Advertisement – Notice of Postal Ballot dated May 22, 2024 |
|
PDF 1.33 MB |
| 26 Jun 2024 | Notice of Postal Ballot dated May 22, 2024 |
|
PDF 735 KB |
| 16 Jun 2024 | Intimation under Reg 39 (3) of LODR – Vibhishanan V |
|
PDF 2.55 MB |
| 14 Jun 2024 | Intimation under Regulation 30 of SEBI LODR |
|
PDF 270 KB |
| 23 May 2024 | Newspaper Advertisement – Audited Financial Results for quarter and financial year ended March 31, 2024 |
|
PDF 1.28 MB |
| 22 May 2024 | Observation Letters from BSE & NSE |
|
PDF 2.06 MB |
| 22 May 2024 | Disposal of Corporate Insolvency Process against Strides Alathur Private Limited |
|
PDF 346 KB |
| 22 May 2024 | Outcome of Board Meeting – Audited Financial Results (Standalone & Consolidated) for quarter and year ended March 31, 2024 & Recommendation of Dividend |
|
PDF 4.89 MB |
| 22 May 2024 | Outcome of Board Meeting – Press Release & Earnings Presentation |
|
PDF 1.54 MB |
| 22 May 2024 | Outcome of Board Meeting – Change in Board composition and Management |
|
PDF 376 KB |
| 22 May 2024 | Outcome of Board Meeting - Allotment of Shares |
|
PDF 288 KB |
| 22 May 2024 | Outcome of Board Meeting - Grant of ESOP |
|
PDF 295 KB |
| 22 May 2024 | Strides receives USFDA approval for Sucralfate Oral Suspension, 1gm/10 mL |
|
PDF 444 KB |
| 21 May 2024 | Intimation under Reg 39 (3) of LODR – Rajagopalan J |
|
PDF 713 KB |
| 10 May 2024 | Strides receives USFDA approval for Sevelamer Carbonate Tablets, 800 mg |
|
PDF 1.11 MB |
| 06 May 2024 | Intimation under Reg 39 (3) of LODR – K Murali |
|
PDF 730 KB |
| 30 Apr 2024 | Voting Results of Postal Ballot pursuant to Reg. 44 of SEBI Listing Regulations – Appointment of Mr. Ameet P Hariani (DIN: 00087866) as Independent Director of the Company |
|
PDF 2.35 MB |
| 29 Apr 2024 | Intimation under Regulation 30 of SEBI Regulations, 2015 (Allotment of shares) |
|
PDF 749 KB |
| 09 Apr 2024 | Strides receives USFDA approval for Fluoxetine Tabs 10 mg and 20 mg |
|
PDF 455 KB |
| 06 Apr 2024 | Completion of US-FDA Inspection at the Formulations Facility of Strides Alathur Private Limited, a wholly owned subsidiary of the Company |
|
PDF 249 KB |
| 29 Mar 2024 | Newspaper Advertisement - Notice of Postal Ballot dated March 27, 2024 |
|
PDF 1.00 MB |
| 28 Mar 2024 | Outcome of Appeal at Hon’ble National Company Law Appellate Tribunal, New Delhi – Corporate Insolvency Process against Strides Alathur stands stayed |
|
PDF 260 KB |
| 28 Mar 2024 | Notice of Postal Ballot dated March 27, 2024 |
|
PDF 586 KB |
| 26 Mar 2024 | Intimation under Regulation 30 of SEBI LODR regarding Strides Alathur |
|
PDF 320 KB |
| 18 Mar 2024 | Intimation under Reg 39 (3) of LODR - Venkat Seetharama Rao Teegala |
|
PDF 318 KB |
| 08 Mar 2024 | Newspaper Publication – Hearing of Petition in the matter of Scheme of Amalgamation between Strides Alathur Private Limited and the Company |
|
PDF 2.61 MB |
| 05 Mar 2024 | Strides receives USFDA approval for Gabapentin Tablets USP, 600 mg and 800 mg |
|
PDF 596 KB |
| 02 Feb 2024 | Intimation under Regulation 30 of SEBI LODR – Investors Presentation |
|
PDF 2 MB |
| 02 Feb 2024 | Intimation under Regulation 30 of SEBI LODR – Update on divestment of Eris Pharma GmbH, Germany |
|
PDF 252 KB |
| 31 Jan 2024 | Newspaper Advertisement – Unaudited Financial Results for quarter and nine months ended December 31, 2023 |
|
PDF 1.22 MB |
| 30 Jan 2024 | Outcome of Board Meeting – Unaudited Financial Results (Standalone & Consolidated) for quarter and nine months ended December 31, 2023 |
|
PDF 642 KB |
| 30 Jan 2024 | Strides reports strong Q3FY24 Revenue and EBITDA |
|
PDF 1.63 MB |
| 30 Jan 2024 | Appointment of Mr. Ameet P Hariani as Independent Director of the Company |
|
PDF 275 KB |
| 30 Jan 2024 | Intimation under Regulation 30 of SEBI Listing Regulations – Corporate Guarantees on behalf of Stelis |
|
PDF 394 KB |
| 30 Jan 2024 | Allotment of Shares |
|
PDF 284 KB |
| 25 Jan 2024 | Strides receives USFDA approval for Pregabalin Capsules |
|
PDF 404 KB |
| 23 Jan 2024 | Intimation under Reg 39 (3) of LODR - Haresh Dave & Karesh Dave |
|
PDF 711 KB |
| 11 Jan 2024 | Intimation under Regulation 30 of SEBI LODR – Divestment of Eris Germany |
|
PDF 432 KB |
| 08 Jan 2024 | Intimation under Reg 39 (3) of LODR - Geeta K Doshi |
|
PDF 878 KB |
| 08 Jan 2024 | Intimation under Reg 39 (3) of LODR - Krishna Kishore Busetty |
|
PDF 475 KB |
| 05 Jan 2024 | Intimation under Regulation 30 of SEBI LODR – Acquisition of additional stake in Neviton |
|
PDF 346 KB |
| 02 Jan 2024 | Intimation under Regulation 30 of SEBI LODR – Investment in AMP Energy |
|
PDF 300 KB |
| Date | Title | Report |
|---|
| 29 Dec 2023 | Intimation under Regulation 30 of SEBI LODR – Update on Sale of Manufacturing Facility in Singapore |
|
PDF 237 KB |
| 29 Dec 2023 | Intimation under Reg 39 (3) of LODR |
|
PDF 525 KB |
| 26 Dec 2023 | Intimation under Reg 39 (3) of LODR |
|
PDF 309 KB |
| 23 Dec 2023 | Update on Stelis Biopharma’s transaction with Syngene for sale of Stelis’ Unit 3 Multi-Model Facility in Bengaluru |
|
PDF 210 KB |
| 21 Dec 2023 | Intimation under Regulation 30 of SEBI LODR – Matter relating to Trinity, South Africa |
|
PDF 304 KB |
| 19 Dec 2023 | Intimation under Reg 39 (3) of LODR |
|
PDF 316 KB |
| 01 Dec 2023 | Strides associate company - Stelis Biopharma announces closure of its transaction with Syngene International Limited |
|
PDF 286 KB |
| 01 Dec 2023 | Strides launches Icosapent Ethyl Acid Soft Gel Capsules in partnership with Amneal |
|
PDF 539 KB |
| 28 Nov 2023 | Intimation under Reg 39 (3) of LODR |
|
PDF 413 KB |
| 23 Nov 2023 | Strides receives USFDA approval for Generic Suprep® Bowel Prep Kit |
|
PDF 451 KB |
| 21 Nov 2023 | Strides receives USFDA approval for Levetiracetam Oral Solution |
|
PDF 406 KB |
| 31 Oct 2023 | Newspaper Advertisement – Unaudited Financial Results for quarter and half year ended September 30, 2023 |
|
PDF 1 MB |
| 31 Oct 2023 | Intimation under Reg 39 (3) of LODR |
|
PDF 377 KB |
| 30 Oct 2023 | Change in SMP |
|
PDF 398 KB |
| 30 Oct 2023 | Q2 – Statement of Deviation/Variation for the quarter ended September 30, 2023 |
|
PDF 457 KB |
| 30 Oct 2023 | Outcome of Board Meeting – Un-Audited Financial Results (Standalone & Consolidated) for quarter and half year ended September 30, 2023 |
|
PDF 738 KB |
| 30 Oct 2023 | Allotment of Shares |
|
PDF 334 KB |
| 30 Oct 2023 | Strides reports Strong Q2FY24 Performance - Revenues at ₹ 10,264m and EBITDA at ₹ 1,801m |
|
PDF 2 MB |
| 27 Oct 2023 | Strides announces sale of manufacturing facility in Singapore for a consideration of $15m |
|
PDF 500 KB |
| 25 Oct 2023 | Intimation under Regulation 30 of SEBI Regulations, 2015 (Allotment of shares) |
|
PDF 367 KB |
| 25 Oct 2023 | Intimation under Reg 39 (3) of LODR |
|
PDF 335 KB |
| 20 Oct 2023 | Intimation under Regulation 30 of SEBI Regulations, 2015 (Allotment of shares) |
|
PDF 334 KB |
| 04 Oct 2023 | Strides receives USFDA approval for Efavirenz, Emtricitabine & Tenofovir Disoproxil Fumurate tablets |
|
PDF 385 KB |
| 03 Oct 2023 | Strides receives USFDA approval for Icosapent Ethyl Capsules - Updated Press Release |
|
PDF 450 KB |
| 25 Sep 2023 | Transaction amongst wholly-owned subsidiaries |
|
PDF 305 KB |
| 25 Sep 2023 | Intimation of Scheme of Arrangement pursuant to Regulation 30 of SEBI Listing Regulations |
|
PDF 2 MB |
| 25 Sep 2023 | Investor call link |
|
PDF 325 KB |
| 23 Sep 2023 | Strides receives USFDA approval for Icosapent Ethyl Capsules |
|
PDF 447 KB |
| 15 Sep 2023 | Strides receives tentative USFDA approval for Dolutegravir/ Lamivudine/ Tenofovir Disproxil Fumurate tablets |
|
PDF 448 KB |
| 14 Sep 2023 | Strides receives tentative USFDA approval for Dolutegravir tablets. |
|
PDF 505 KB |
| 09 Sep 2023 | Strides receives USFDA approval for Sevelamer Carbonate for Oral Suspension. |
|
PDF 442 KB |
| 07 Sep 2023 | Intimation under Regulation 30 of SEBI LODR - Internal Restructuring of Strides Pharma Services Private Limited, a group entity. |
|
PDF 298 KB |
| 06 Sep 2023 | Intimation under Reg 39 (3) of LODR |
|
PDF 426 KB |
| 01 Sep 2023 | Intimation under Regulation 30 of SEBI Regulations, 2015 (Change in Senior Management) |
|
PDF 315 KB |
| 30 Aug 2023 | Strides receives USFDA approval for Mycophenolate Mofetil for Oral Suspension |
|
PDF 447 KB |
| 30 Aug 2023 | Outcome of 32nd Annual General Meeting of the Company |
|
PDF 884 KB |
| 29 Aug 2023 | Intimation under Regulation 30 of SEBI Listing Regulations – Corporate Guarantees on behalf of Stelis |
|
PDF 426 KB |
| 29 Aug 2023 | Intimation under Reg 39 (3) of LODR |
|
PDF 311 KB |
| 28 Aug 2023 | Proceedings of AGM |
|
PDF 497 KB |
| 22 Aug 2023 | Intimation under Reg 39 (3) of LODR |
|
PDF 385 KB |
| 16 Aug 2023 | Intimation under Regulation 30 of SEBI Listing Regulations (CGs and Litigations) |
|
PDF 810 KB |
| 05 Aug 2023 | Newspaper Publication titled ‘Notice of 32nd Annual General Meeting, Remote E-Voting and Cut-Off Date’ |
|
PDF 1.63 MB |
| 04 Aug 2023 | Notice of the 32nd Annual General Meeting and Annual Report for FY 2022-23 |
|
PDF 6 MB |
| 04 Aug 2023 | Submission of Business Responsibility & Sustainability Report for FY23 |
|
PDF 605 KB |
| 03 Aug 2023 | Unaudited Financial Results for the quarter ended June 30, 2023 |
|
PDF 4 MB |
| 03 Aug 2023 | Intimation under Reg 39 (3) of LODR |
|
PDF 377 KB |
| 02 Aug 2023 | Intimation under SEBI (Prohibition of Insider Trading) Regulations, 2015 |
|
PDF 466 KB |
| 02 Aug 2023 | Intimation of Scheme of Amalgamation under Regulation 30 of the SEBI Listing Regulations |
|
PDF 385 KB |
| 02 Aug 2023 | Outcome of Board Meeting – Un-Audited Financial Results (Standalone & Consolidated) for quarter ended June 30, 2023 |
|
PDF 629 KB |
| 02 Aug 2023 | Strides reports highest ever EBITDA, INR 1,686m in Q1FY24 |
|
PDF 2 MB |
| 28 July 2023 | Outcome of Postal Ballot |
|
PDF 1 MB |
| 19 July 2023 | Intimation under Reg 39 (3) of LODR |
|
PDF 297 KB |
| 12 July 2023 | Intimation under Reg 39 (3) of LODR |
|
PDF 381 KB |
| 07 July 2023 | Allotment of shares under Strides ESOP Plan 2016 |
|
PDF 1 MB |
| 04 July 2023 | Stelis Biopharma enters into a binding term sheet with Syngene International Limited to divest its Unit 3 multi-modal facility for a gross consideration of INR 7,020 million |
|
PDF 1 MB |
| 29 June 2023 | Intimation under Reg 39 (3) of LODR |
|
PDF 301 KB |
| 28 June 2023 | Intimation under Reg 39 (3) of LODR |
|
PDF 301 KB |
| 27 June 2023 | Newspaper Advertisement - Notice of Postal Ballot dated May 25, 2023 |
|
PDF 1 MB |
| 26 June 2023 | Notice of Postal Ballot dated May 25, 2023 |
|
PDF 233 KB |
| 26 June 2023 | Intimation under Reg 39 (3) of LODR |
|
PDF 382 KB |
| 23 June 2023 | Intimation under Reg 39 (3) of LODR |
|
PDF 369 KB |
| 16 June 2023 | Intimation under Reg 39 (3) of LODR |
|
PDF 364 KB |
| 30 May 2023 | Annual Secretarial Compliance Report for the year ended March 31, 2023 |
|
PDF 723 KB |
| 30 May 2023 | Annual Secretarial Compliance Report for the year ended March 31, 2023 |
|
PDF 233 KB |
| 25 May 2023 | Disclosure of Related Party Transactions for the half year ended March 31, 2023 |
|
PDF 233 KB |
| 25 May 2023 | Disclosure of Related Party Transactions for the half year ended March 31, 2023 |
|
PDF 584 KB |
| 25 May 2023 | Grant of Options under Strides ESOP Plan 2016 |
|
PDF 298 KB |
| 25 May 2023 | Strides reports strong Q4FY23 results and lays the foundation for a promising FY24 |
|
PDF 2 MB |
| 25 May 2023 | Outcome of Board Meeting - Audited Financial Results (Standalone & Consolidated) for quarter and year ended March 31, 2023 |
|
PDF 826 KB |
| 24 May 2023 | Newspaper Adv - Notice for transferring of equity shares to IEPF |
|
PDF 350 KB |
| 19 May 2023 | Strides Puducherry facility receives Establishment Inspection Report (EIR) from USFDA confirming the reclassification of the site from Official Action Indicated (OAI) to Voluntary Action Indicated (VAI) |
|
PDF 263 KB |
| 19 May 2023 | Intimation under Reg 39 (3) of LODR |
|
PDF 365 KB |
| 18 May 2023 | Intimation of Board Meeting scheduled on May 25, 2023 |
|
PDF 325 KB |
| 3 May 2023 | Strides and Orbicular enter into a strategic partnership to jointly develop a range of nasal sprays |
|
PDF 3.3 MB |
| 24 Apr 2023 | Intimation under Reg 39 (3) of LODR |
|
PDF 368 KB |
| 17 Apr 2023 | Intimation under Reg 39 (3) of LODR |
|
PDF 417 KB |
| 23 Mar 2023 | Outcome of Postal Ballot |
|
PDF 3.3 MB |
| 20 Mar 2023 | Intimation under Reg 39 (3) of LODR |
|
PDF 432 KB |
| 14 Mar 2023 | Intimation pursuant to Regulation 31A of SEBl Listing Regulations |
|
PDF 458 KB |
| 24 Feb 2023 | Strides flagship facility in Bangalore receives USFDA inspection closure |
|
PDF 389 KB |
| 23 Feb 2023 | Intimation pursuant to Regulation 31A of SEBl Listing Regulations |
|
PDF 532 KB |
| 16 Feb 2023 | Intimation under Reg 39 (3) of LODR |
|
PDF 330 KB |
| 06 Feb 2023 | Notice of Postal Ballot – January 24, 2023 |
|
PDF 532 KB |
| 06 Feb 2023 | Outcome of Extraordinary General Meeting of the Company held on February 6, 2023 |
|
PDF 660 KB |
| 06 Feb 2023 | Proceedings of Extraordinary General Meeting of the Company held on February 6, 2023 |
|
PDF 422 KB |
| 25 Jan 2023 | Earnings call Audio link Dec qtr |
|
PDF 274 KB |
| 24 Jan 2023 | Outcome of Board Meeting – Unaudited Financial Results (Standalone & Consolidated) for the quarter and nine months ended Dec 31, 2022 |
|
PDF 3.81 MB |
| 24 Jan 2023 | Grant of Options under Strides ESOP Plan 2016 |
|
PDF 272 KB |
| 23 Jan 2023 | Earnings call intimation_Dec qtr |
|
PDF 565 KB |
| 20 Jan 2023 | Completion of the WHO PQ inspection at the Puducherry facility of the Company |
|
PDF 275 KB |
| 18 Jan 2023 | Stelis Biopharma’s flagship facility receives EIR from the USFDA on the successful closure of its inspection specific to Drug-Device Combination Products |
|
PDF 391 KB |
| 13 Jan 2023 | Notice of Extraordinary General Meeting scheduled to be held on February 6, 2023 |
|
PDF 499 KB |
| Date | Title | Report |
|---|
| 27 May 2022 | Newspaper Adv - Notice for transferring of equity shares to IEPF | |
PDF 342 KB |
| 28 Dec 2022 | Stelis Biopharma’s CDMO partner receives approval for a key ANDA from the USFDA | |
PDF 389 KB |
| 23 Dec 2022 | Intimation under Reg 39 (3) of LODR | |
PDF 367 KB |
| 22 Dec 2022 | Receipt of AUD 94 million on account of deferred consideration on the sale of the Company’s Australian operations in 2019 | |
PDF 273 KB |
| 12 Dec 2022 | Intimation under Reg 39 (3) of LODR | |
PDF 297 KB |
| 1 Dec 2022 | Intimation under Reg 39 (3) of LODR | |
PDF 2.29 MB |
| 28 Nov 2022 | RPT Disclosure for the half year ended Sept 30, 2022 | |
PDF 2.51 MB |
| 18 Nov 2022 | Strides receives USFDA approval for Potassium Chloride Oral Solution | |
PDF 2.30 MB |
| 16 Nov 2022 | Earnings Call Audio link_Sept quarter | |
PDF 2.20 MB |
| 14 Nov 2022 | Resignation of Mr. Deepak Calian Vaidya, Non-Executive Director | |
PDF 2.21 MB |
| 14 Nov 2022 | Allotment of shares under Strides ESOP Plan 2016 | |
PDF 2.21 MB |
| 14 Nov 2022 | Grant of Options under Strides ESOP Plan 2016 | |
PDF 2.20 MB |
| 14 Nov 2022 | Outcome of Board Meeting – Unaudited Financial Results (Standalone & Consolidated) for the quarter and half year ended Sept 30, 2022 | |
PDF 4.82 MB |
| 14 Nov 2022 | Stelis receives a positive recommendation from European Medicines Agency (EMA) granting market authorization for KaulivTM, a recombinant human teriparatide biosimilar to treat osteoporosis | |
PDF 2.30 MB |
| 11 Nov 2022 | Earnings Call intimation_Sept quarter | |
PDF 2.60 MB |
| 21 Oct 2022 | Intimation under Reg 39 (3) of LODR | |
PDF 1.60 MB |
| 19 Oct 2022 | Intimation under Reg 39 (3) of LODR | |
PDF 233 KB |
| 16 Sep 2022 | Allotment of Shares - Sep 16, 2022 | |
PDF 395 KB |
| 15 Sep 2022 | Intimation under Reg 39 (3) of LODR | |
PDF 1.90 MB |
| 08 Sep 2022 | Outcome of the 31st Annual General Meeting of the Company – Reappointment of Statutory Auditors | |
PDF 311 KB |
| 08 Sep 2022 | Outcome of the 31st Annual General Meeting of the Company | |
PDF 698 KB |
| 08 Sep 2022 | Proceedings of the 31st Annual General Meeting of the Company held on September 9, 2022 | |
PDF 433 KB |
| 08 Sep 2022 | Allotment of Shares_Sep 8, 2022 | |
PDF 243 KB |
| 02 Sep 2022 | Allotment of Shares_Sep 2, 2022 | |
PDF 288 KB |
| 01 Sep 2022 | Stelis Biopharma’s flagship facility receives USFDA nod for Drug Product Capabilities | |
PDF 409 KB |
| 30 Aug 2022 | Intimation under Reg 39 (3) of LODR | |
PDF 303 KB |
| 26 Aug 2022 | Press release issued by Universal Corporation Ltd., a Strides Pharma Science Limited Enterprise titled “First African-manufactured medicine to prevent malaria in pregnant women and infants quality - approved by WHO” | |
PDF 421 KB |
| 18 Aug 2022 | Notice of the 31st Annual General Meeting and Annual Report for FY 2021-22 | |
PDF 5.16 MB |
| 18 Aug 2022 | Strides receives USFDA approval for Naproxen Sodium OTC Softgel Capsules | |
PDF 354 KB |
| 08 Aug 2022 | Strides announces successful completion of US FDA inspection at its Singapore facility | |
PDF 376 KB |
| 03 Aug 2022 | Strides receives USFDA approval for Cyclosporine Softgel Capsules | |
PDF 681 KB |
| 02 Aug 2022 | Intimation under Reg 39 (3) of LODR | |
PDF 348 KB |
| 30 Jul 2022 | Earnings Call Audio link_June quarter | |
PDF 310 KB |
| 29 Jul 2022 | Grant of Options under Strides ESOP Plan 2016 | |
PDF 238 KB |
| 29 Jul 2022 | Outcome of Board Meeting – Unaudited Financial Results (Standalone & Consolidated) for the quarter ended June 30, 2022 | |
PDF 2.8 MB |
| 28 Jul 2022 | Earnings Call intimation_June quarter | |
PDF 587 KB |
| 19 Jul 2022 | Intimation under Reg 39 (3) of LODR | |
PDF 381 KB |
| 14 Jul 2022 | Intimation under Reg 39 (3) of LODR | |
PDF 443 KB |
| 12 Jul 2022 | Intimation under Reg 39 (3) of LODR | |
PDF 299 KB |
| 07 Jul 2022 | Outcome of the Postal Ballot Notice dated May 24, 2022 | |
PDF 5 MB |
| 30 Jun 2022 | Intimation under Reg 39 (3) of LODR | |
PDF 209 KB |
| 28 Jun 2022 | Intimation under Reg 39 (3) of LODR | |
PDF 300 KB |
| 24 Jun 2022 | Biolexis and Akston Biosciences Announce Encouraging Top-Line Results from Phase II/III Trial of their Thermostable 2nd Gen COVID-19 Vaccine | |
PDF 344 KB |
| 17 Jun 2022 | Intimation under Reg 39 (3) of LODR | |
PDF 382 KB |
| 16 Jun 2022 | Stelis Biopharma’s two biologics manufacturing facilities receive EU cGMP accreditation | |
PDF 354 KB |
| 10 Jun 2022 | Strides receives USFDA approval for Ibuprofen OTC Oral Suspension | |
PDF 379 KB |
| 08 Jun 2022 | Disclosure of Related Party Transactions for half year ended March 31, 2022 | |
PDF 432 KB |
| 01 Jun 2022 | Transcript of Earnings call | |
PDF 417 KB |
| 30 May 2022 | Strides receives USFDA approval for Ibuprofen Oral Suspension | |
PDF 314 KB |
| 25 May 2022 | Audio Recording of Earnings call pertaining to the Financial Results for the Quarter and Financial Year Ended March 31, 2022. | |
PDF 233 KB |
| 24 May 2022 | Grant of Options under Strides ESOP Plan 2016 | |
PDF 230 KB |
| 24 May 2022 | Outcome of Board Meeting - Disclosure under Regulation 30 of SEBI Listing Regulations | |
PDF 5.6 MB |
| 15 May 2022 | Clarification on news item appeared online based on a report filed by Press Trust of India (PTI) titled “Unable to sell Sputnik Light stock, Stelis Biopharma requests PM Modi for procurement of jabs. | |
PDF 319 KB |
| 13 May 2022 | Intimation under Reg 39 (3) of LODR | |
PDF 498 KB |
| 06 May 2022 | Intimation under Reg 39 (3) of LODR | |
PDF 324 KB |
| 02 May 2022 | Intimation under Reg 39 (3) of LODR | |
PDF 236 KB |
| 25 Apr 2022 | Intimation under Reg 39 (3) of LODR | |
PDF 387 KB |
| 18 Apr 2022 | Allotment of shares under Strides ESOP 2016 Plan | |
PDF 170 KB |
| 09 Apr 2022 | Outcome of the Extraordinary General Meeting of the Company | |
PDF 4.71 MB |
| 07 Apr 2022 | Proceedings of the Extraordinary General Meeting of the Company | |
PDF 389 KB |
| 29 Mar 2022 | Strides announces Leadership changes | |
PDF 453 KB |
| 29 Mar 2022 | Intimation under Regulation 30 of the SEBI Listing Regulations | |
PDF 441 KB |
| 24 Mar 2022 | Intimation under Reg 39 (3) of LODR | |
PDF 405 KB |
| 21 Mar 2022 | Strides partners with Medicines Patent Pool (MPP) to commercialize the generic version of Pfizer’s COVID-19 Oral Treatment across 95 markets | |
PDF 366 KB |
| 17 Mar 2022 | Akston Biosciences and Biolexis Collaborate to Launch a Room Temperature Stable 2nd Generation COVID-19 Vaccine in 130+ Countrie | |
PDF 453 KB |
| 16 Mar 2022 | Intimation under Reg 39 (3) of LODR | |
PDF 264 KB |
| 14 Mar 2022 | Update on Proposed Preferential Issue | |
PDF 989 KB |
| 11 Mar 2022 | Strides receives USFDA approval for Colchicine Tablets | |
PDF 372 KB |
| 21 Feb 2022 | USFDA approval for Amantadine Hydrochloride Softgel Capsules | |
PDF 378 KB |
| 15 Feb 2022 | Intimation under Reg 39 (3) of LODR | |
PDF 301 KB |
| 17 Feb 2022 | Intimation regarding rescheduling of Extraordinary General Meeting | |
PDF 243 KB |
| 10 Feb 2022 | Intimation of Scheme of Amalgamation under Regulation 30 of the SEBI Listing Regulations | |
PDF 263 KB |
| 10 Feb 2022 | Outcome of Board Meeting - Disclosure under Regulation 30 of SEBI Listing Regulations | |
PDF 356 KB |
| 10 Feb 2022 | Outcome of Board Meeting - Unaudited Financial Results (Standalone & Consolidated) for the quarter and nine months ended December 31, 2021 | |
PDF 2.3 MB |
| 09 Feb 2022 | Intimation pursuant to Regulation 31A of the SEBI Listing Regulations | |
PDF 409 KB |
| 07 Feb 2022 | Fund raising - Intimation under Regulation 29(2) of the SEBI Listing Regulations. | |
PDF 274 KB |
| 03 Feb 2022 | Intimation under Reg 39 (3) of LODR | |
PDF 314 KB |
| 28 Jan 2022 | SE Intimation | |
PDF 315 KB |
| 20 Jan 2022 | Strides and its African subsidiary Universal Corporation partner with Medicines Patent Pool (MPP) to commercialize molnupiravir for the global markets | |
PDF 499 KB |
| 18 Jan 2022 | Outcome of the Postal Ballot Notice dated November 10, 2021 | |
PDF 5.8 MB |
| 17 Jan 2022 | Strides receives USFDA approval for Oseltamivir Phosphate for Oral Suspension | |
PDF 377 KB |
| Date | Title | Report |
|---|
| 31 Dec 2021 | Intimation under Reg 39 (3) of LODR | |
PDF 428 KB |
| 28 Dec 2021 | Strides receives DCGI approval under EUA to commercialize Molnupiravir, an oral medication for Covid-19 | |
PDF 228 KB |
| 21 Dec 2021 | Stelis Biopharma commissions its greenfield vaccine manufacturing facility at Bengaluru, India, successfully completes the CDSCO inspection for Drug Substance and Drug Product, and receives initial NOC to export 50 million doses of Russian Sputnik Light Vaccine | |
PDF 253 KB |
| 15 Dec 2021 | Notice of Postal Ballot dated November 10, 2021 | |
PDF 725 KB |
| 10 Nov 2021 | Intimation under Reg 31A of LODR – Board approval for Reclassification | |
PDF 447 KB |
| 10 Nov 2021 | Intimation under Reg 30 of LODR – Postal Ballot Matters | |
PDF 649 KB |
| 10 Nov 2021 | Intimation under PIT Regulations – Strides’ Fair Disclosure Code | |
PDF 4.1 MB |
| 10 Nov 2021 | Outcome of Board Meeting – Un-Audited Financial Results (Standalone & Consolidated) for the quarter and half year ended September 30, 2021 | |
PDF 4.1 MB |
| 01 Nov 2021 | Allotment of shares under Strides ESOP 2016 Plan | |
PDF 157 KB |
| 28 Oct 2021 | Intimation under Reg 39 (3) of LODR | |
PDF 393 KB |
| 22 Oct 2021 | SE Intimation | |
PDF 463 KB |
| 22 Oct 2021 | Request received for reclassification of shareholding from ‘Promoter/ Promoter Group’ to ‘Public’ Category’ | |
PDF 998 KB |
| 22 Oct 2021 | Intimation under Reg 39 (3) of LODR | |
PDF 448 KB |
| 21 Oct 2021 | Strides announces completion of transaction to acquire manufacturing facility in the US along with basket of ANDAs from Endo International plc | |
PDF 173 KB |
| 12 Oct 2021 | Intimation pursuant to Regulation 31A of the SEBl Listing Regulations – Approval received from BSE and NSE for reclassification of SeQuent Scientific Limited from ‘Promoter Group’ to ‘Public’ Category. | |
PDF 509 KB |
| 01 Oct 2021 | Intimation under Regulation 30 of SEBI Listing Regulations regarding termination of Shareholders’ Agreement of May 16, 2016 | |
PDF 292 KB |
| 14 Sep 2021 | SE Intimation | |
PDF 385 KB |
| 06 Sep 2021 | SE Intimation | |
PDF 408 KB |
| 06 Sep 2021 | SE Intimation | |
PDF 456 KB |
| 04 Sep 2021 | Outcome of the 30th Annual General Meeting of the Company | |
PDF 2.43 MB |
| 03 Sep 2021 | SE Intimation | |
PDF 373 KB |
| 03 Sep 2021 | Proceedings of the 30th Annual General Meeting of the Company | |
PDF 501 KB |
| 11 Aug 2021 | Notice of 30th Annual General Meeting and Annual Report for FY 2020-21 | |
PDF 4.12 MB |
| 06 Aug 2021 | Stelis Biopharma - Q1 FY22 Investor Update | |
PDF 1.83 MB |
| 06 Aug 2021 | Stelis Biopharma strengthens its Board with experienced industry leadership and diversity | |
PDF 257 KB |
| 06 Aug 2021 | Stelis Biopharma appoints Mark W. Womack as the new CEO | |
PDF 255 KB |
| 06 Aug 2021 | Outcome of Board Meeting – Un-Audited Financial Results (Standalone & Consolidated) for the quarter ended June 30, 2021 | |
PDF 1.76 MB |
| 06 Aug 2021 | Allotment of Shares under Strides ESOP Plan 2016 | |
PDF 198 KB |
| 06 Aug 2021 | Strides inks definitive agreement with Endo to acquire its manufacturing facility in the US along with basket of ANDAs | |
PDF 392 KB |
| 04 Aug 2021 | SE Intimation | |
PDF 444 KB |
| 26 Jul 2021 | Intimation to Members about Annual General Meeting of the Company and Record Date for the purpose of Final Dividend | |
PDF 352 KB |
| 30 Jun 2021 | Allotment of shares under Strides ESOP 2016 Plan | |
PDF 356 KB |
| 29 Jun 2021 | Annual Secretarial Compliance Report for the year ended March 31, 2021 | |
PDF 1.72 MB |
| 28 Jun 2021 | Strides announces successful completion of EU GMP inspection at Puducherry facility | |
PDF 384 KB |
| 25 Jun 2021 | Disclosure of Related Party Transactions for the year ended March 31, 2021 | |
PDF 441 KB |
| 22 Jun 2021 | Appointment of Chief Human Resource Officer | |
PDF 243 KB |
| 16 Jun 2021 | SE Intimation | |
PDF 247 KB |
| 14 Jun 2021 | Ennaid Therapeutics partners exclusively with Strides to manufacture life-saving oral Covid-19 Tablet | |
PDF 476 KB |
| 12 Jun 2021 | Outcome of Postal Ballot – Re-appointment of Mr. Bharat Shah as an Independent Director of the Company | |
PDF 2.96 MB |
| 10 Jun 2021 | SE intimation | |
PDF 327 KB |
| 27 May 2021 | Outcome of Board Meeting - Audited Financial Results (Standalone & Consolidated) for the quarter and year ended March 31, 2021 | |
PDF 1.06 MB |
| 27 May 2021 | Recommendation of Final Dividend for the financial year ended March 31, 2021 | |
PDF 230 KB |
| 27 May 2021 | Grant of Options under Strides ESOP Plan 2016 | |
PDF 174 KB |
| 27 May 2021 | Allotment of shares under Strides ESOP 2016 Plan | |
PDF 202 KB |
| 27 May 2021 | TLC and Strides partner to launch Liposomal Amphotericin B in India | |
PDF 485 KB |
| 25 May 2021 | Update on completion of Series C funding in Stelis | |
PDF 277 KB |
| 12 May 2021 | SE Intimation - Notice of Postal Ballot | |
PDF 457 KB |
| 10 May 2021 | Intimation on re-appointment of Independent Director of the Company | |
PDF 263 KB |
| 03 May 2021 | SE Intimation | |
PDF 263 KB |
| 12 Apr 2021 | Intimation pursuant to Regulation 31A of SEBl Listing Regulations | |
PDF 233 KB |
| 31 Mar 2021 | SE Intimation | |
PDF 566 KB |
| 19 Mar 2021 | RDIF and Stelis Biopharma partner to supply 200 million doses of the Sputnik V vaccine | |
PDF 326 KB |
| 19 Mar 2021 | Stelis concludes US$ 195m Series B and Series C fund raise Significant interest from marquee long term investors | |
PDF 439 KB |
| 17 Mar 2021 | Strides – Outcome of Postal Ballot – Relating to SeQuent Reclassification | |
PDF 2.6 MB |
| 15 Mar 2021 | Strides receives USFDA approval for Potassium Chloride for Oral Solution | |
PDF 402 KB |
| 05 Mar 2021 | SE Intimation | |
PDF 196 KB |
| 03 Mar 2021 | Intimation under Reg 39 (3) of LODR | |
PDF 319 KB |
| 24 Feb 2021 | Strides receives USFDA approval for Ibuprofen OTC Oral Suspension | |
PDF 369 KB |
| 12 Feb 2021 | Strides receives USFDA approval for Prednisone Tablets | |
PDF 307 KB |
| 10 Feb 2021 | SE Intimation - Notice of Postal Ballot | |
PDF 612 KB |
| 09 Feb 2021 | Intimation under Reg 39 (3) of LODR | |
PDF 322 KB |
| 04 Feb 2021 | Strides Outcome of Board Meeting | |
PDF 2.4 MB |
| 04 Feb 2021 | Strides allotment of shares | |
PDF 202 KB |
| 04 Feb 2021 | Strides Press Release - Relating to Stelis | |
PDF 398 KB |
| 25 Jan 2021 | Strides receives USFDA approval for Ursodiol Capsules | |
PDF 308 KB |
| 22 Jan 2021 | India Ratings upgrades Strides Pharma Science Limited to ‘IND A+’; Outlook Stable | |
PDF 238 KB |
| 15 Jan 2021 | Strides receives USFDA approval for Emtricitabine and Tenofovir Disoproxil Fumarate Tablets | |
PDF 366 KB |
| 08 Jan 2021 | Aditya Puri joins as Advisor to the Strides Group & Director of Stelis Biopharma | |
PDF 318 KB |
| Date | Title | Report |
|---|
| 18 Dec 2020 | Strides receives USFDA approval for Oxybutynin Chloride Tablets | |
PDF 364 KB |
| 26 Nov 2020 | Disclosure of Related Party Transactions for the half year ended September 30, 2020 | |
PDF 540 KB |
| 23 Nov 2020 | Strides receives USFDA approval for Prednisone Tablets | |
PDF 367 KB |
| 12 Nov 2020 | Receipt of NCLT Mumbai Bench Order | |
PDF 226 KB |
| 06 Nov 2020 | Intimation under Reg 39 (3) of LODR | |
PDF 787 KB |
| 29 Oct 2020 | Strides Outcome of BM Results | |
PDF 7.61 MB |
| 29 Oct 2020 | Strides Allotment of shares under ESOP | |
PDF 202 KB |
| 29 Oct 2020 | Strides Board Approval Sequent reclassification | |
PDF 485 KB |
| 29 Oct 2020 | Strides Vivimed Merger Reg30 | |
PDF 315 KB |
| 20 Oct 2020 | Strides receives USFDA approval for Ethacrynic Acid Tablets | |
PDF 368 KB |
| 22 Sep 2020 | Strides receives USFDA approval for Butalbital, Acetaminophen, and Caffeine Tablets | |
PDF 368 KB |
| 16 Sep 2020 | Intimation under Reg 39 (3) of LODR | |
PDF 341 KB |
| 15 Sep 2020 | Intimation under Reg 39 (3) of LODR | |
PDF 967 KB |
| 14 Sep 2020 | Disclosure under Reg 30 of SEBI LODR relating to Press Release dated Sep 14, 2020 | |
PDF 331 KB |
| 14 Sep 2020 | Strides unveils SteriScience as its dedicated arm for sterile injectables | |
PDF 1.19 MB |
| 03 Sep 2020 | Strides receives USFDA approval for Prednisone Tablets | |
PDF 363 KB |
| 31 Aug 2020 | Strides Allotment of shares | |
PDF 241 KB |
| 21 Aug 2020 | Strides AGM SEBI Results and Scrutinizer Report | |
PDF 5.34 MB |
| 21 Aug 2020 | Strides receives USFDA approval for Ursodiol Tablets | |
PDF 197 KB |
| 20 Aug 2020 | Strides Intimation of Proceeding of AGM | |
PDF 250 KB |
| 19 Aug 2020 | Strides announces successful completion of UK MHRA inspection at Puducherry facility | |
PDF 210 KB |
| 05 Aug 2020 | Strides Outcome of the BM Results | |
PDF 2.26 MB |
| 05 Aug 2020 | Strides intimation allotment of shares | |
PDF 102 KB |
| 29 Jul 2020 | Strides Book Closure for AGM | |
PDF 149 KB |
| 29 Jul 2020 | Notice of 29th Annual General Meeting and Annual Report for FY 2019-2020 | |
PDF 3.87 MB |
| 15 Jul 2020 | 29th Annual General Meeting / Record date | |
PDF 209 KB |
| 09 Jul 2020 | Strides receives USFDA approval for Butalbital, Acetaminophen, Caffeine, and Codeine Phosphate Capsules | |
PDF 309 KB |
| 19 Jun 2020 | NCLT Order of Blore Bench Merger of WoS | |
PDF 168 KB |
| 18 Jun 2020 | Disclosure of Related Party Transactions for the year ended March 31, 2020 | |
PDF 276 KB |
| 10 Jun 2020 | Intimation under Reg 39 (3) of LODR | |
PDF 150 KB |
| 02 Jun 2020 | Strides receives USFDA approval for Triamcinolone Acetonide Ointment | |
PDF 299 KB |
| 22 May 2020 | Strides SE Intimation | |
PDF 143 KB |
| 20 May 2020 | Outcome of Board Meeting Results | |
PDF 3.36 MB |
| 20 May 2020 | Outcome of Board Meeting - Final Dividend | |
PDF 126 KB |
| 20 May 2020 | Allotment of shares under ESOP | |
PDF 127 KB |
| 20 May 2020 | Grant of Stock Options | |
PDF 970 KB |
| 29 Apr 2020 | Strides develops and commences export of Favipiravir Antiviral Tablets | |
PDF 327 KB |
| 20 Apr 2020 | Strides receives USFDA approval for Flucytosine Capsules | |
PDF 256 KB |
| 02 Apr 2020 | Strides provides updates as USFDA requests all manufacturers to withdraw Ranitidine products from the US Market | |
PDF 283 KB |
| 30 Mar 2020 | Strides announces successful completion of US FDA inspection conducted in January 2020 at flagship facility in Bangalore | |
PDF 256 KB |
| 26 Mar 2020 | EIR from USFDA on continued GMP status for the flagship facility in Bangalore | |
PDF 148 KB |
| 13 Mar 2020 | Intimation under Reg 39 (3) of LODR | |
PDF 614 KB |
| 04 Mar 2020 | Strides receives USFDA approval for Tetracycline Hydrochloride Capsules | |
PDF 236 KB |
| 21 Feb 2020 | Outcome of NCLT Meeting | |
PDF 661 KB |
| 18 Feb 2020 | Intimation under Reg 39 (3) of LODR | |
PDF 911 KB |
| 07 Feb 2020 | Strides to acquire 18 ANDAs from Pharmaceutics International, Inc. | |
PDF 300 KB |
| 31 Jan 2020 | Intimation of Investors / Analysts Meet | |
PDF 230 KB |
| 30 Jan 2020 | SE Intimation Scheme of Amalgamation | |
PDF 492 KB |
| 30 Jan 2020 | Outcome of Board Meeting Results | |
PDF 4.16 MB |
| 30 Jan 2020 | SE Intimation allotment of shares - ESOP | |
PDF 106 KB |
| 29 Jan 2020 | Intimation under Reg 39 (3) of LODR | |
PDF 727 KB |
| 28 Jan 2020 | Strides Earnings Call Invite | |
PDF 174 KB |
| 24 Jan 2020 | Strides announces the successful completion of US FDA inspection at its Alathur facility with “Zero 483 observations” | |
PDF 269 KB |
| 24 Jan 2020 | USFDA tentative approval for Triamcinolone Acetonide Ointment | |
PDF 169 KB |
| 20 Jan 2020 | Strides announces successful closure of the USFDA inspection at its manufacturing site in Florida, United States | |
PDF 1.19 MB |
| 17 Jan 2020 | SPSL Intimation to SE Tribunal Meeting | |
PDF 7.86 MB |
| 16 Jan 2020 | USFDA approval for Loratadine OTC Softgel Capsules | |
PDF 178 KB |
| 08 Jan 2020 | Dr. R Ananthanarayanan appointed as the new CEO & Managing Director of Strides | |
PDF 212 KB |
| 08 Jan 2020 | Press Release on appointment of new CEO & MD | |
PDF 251 KB |
| 08 Jan 2020 | SE Intimation on appointment of new CEO & MD | |
PDF 63 KB |
| 08 Jan 2020 | SE Intimation on KMP | |
PDF 83 KB |
| 08 Jan 2020 | Intimation under Reg 39 (3) of LODR | |
PDF 914 KB |
| Date | Title | Report |
|---|
| 24 Dec 2019 | Intimation under Reg 39 (3) of LODR | |
PDF 564 KB |
| 19 Dec 2019 | SE Intimation | |
PDF 419 KB |
| 17 Dec 2019 | SE Intimation | |
PDF 427 KB |
| 11 Dec 2019 | Intimation on Appointment of ID | |
PDF 64 KB |
| 05 Dec 2019 | Intimation of Investor/ Analyst Day | |
PDF 147 KB |
| 04 Dec 2019 | USFDA tentative approval for Diclofenac Potassium Softgel Capsules | |
PDF 406 KB |
| 27 Nov 2019 | SE Intimation | |
PDF 314 KB |
| 25 Nov 2019 | Outcome of Postal Ballot – CG to Stelis | |
PDF 1.06 MB |
| 22 Nov 2019 | Disclosure of Related Party Transactions for the half year ended September 30, 2019 | |
PDF 227 KB |
| 08 Nov 2019 | Strides announces relaunch of Ranitidine tablets (Rx) for the US Market | |
PDF 402 KB |
| 06 Nov 2019 | Intimation SE Merger of WoS | |
PDF 1.67 MB |
| 04 Nov 2019 | Strides’ Ranitidine Tablets 300 mg lots tested by USFDA are within the acceptable NDMA limits | |
PDF 181 KB |
| 25 Oct 2019 | Outcome of Board Meeting of Oct 25, 19 - Allotment of shares | |
PDF 421 KB |
| 25 Oct 2019 | Outcome of Board Meeting of Oct 25, 19_Grant of Options | |
PDF 50 KB |
| 25 Oct 2019 | Outcome of Board Meeting of Oct 25, 19 - Unaudited results | |
PDF 3.01 MB |
| 25 Oct 2019 | SPSL Earnings Call Intimation | |
PDF 176 KB |
| 23 Oct 2019 | TGA, Australia announces Ranitidine test results | |
PDF 421 KB |
| 23 Oct 2019 | EIR from USFDA on continued GMP status for formulation facility at Alathur | |
PDF 146 KB |
| 22 Oct 2019 | SE Intimation of Postal Ballot and Evoting | |
PDF 870 KB |
| 04 Oct 2019 | Update on Encumbrance by Promoters | |
PDF 1.98 MB |
| 27 Sep 2019 | Strides receives USFDA approval for Solifenacin Succinate Tablets | |
PDF 304 KB |
| 27 Sep 2019 | Further Updates on Ranitidine Tablets for the US Markets | |
PDF 146 KB |
| 25 Sep 2019 | Update on Ranitidine tablets | |
PDF 224 KB |
| 20 Sep 2019 | Strides Board approves incremental investments in Stelis | |
PDF 316 KB |
| 20 Sep 2019 | Strides Board approves incremental investments in Stelis | |
PDF 227 KB |
| 20 Sep 2019 | Grant of Options under Strides Employee Stock Option Plan 2016 | |
PDF 52 KB |
| 11 Sep 2019 | Strides acquires strategic stake in Fairmed Healthcare AG in Europe | |
PDF 320 KB |
| 06 Sep 2019 | SE Intimation | |
PDF 302 KB |
| 28 Aug 2019 | SE Intimation | |
PDF 196 KB |
| 27 Aug 2019 | Strides acquires USFDA approved manufacturing facility in the US | |
PDF 349 KB |
| 09 Aug 2019 | Successful completion of US FDA inspection at its Alathur facility with "Zero 483 observations" | |
PDF 1.4 MB |
| 31 Jul 2019 | Intimation on proceeding of 28th AGM – July 30, 2019 | |
PDF 174 KB |
| 31 Jul 2019 | Outcome of 28th AGM – July 30, 2019 | |
PDF 1.64 MB |
| 31 Jul 2019 | Update | |
PDF 125 KB |
| 29 Jul 2019 | Strides Outcome of the BM | |
PDF 3.19 MB |
| 29 Jul 2019 | SE Intimation Grant of Options | |
PDF 55 KB |
| 29 Jul 2019 | Strides Outcome of the BM - Dividend | |
PDF 57 KB |
| 29 Jul 2019 | SPSL 2019 Merger-Intimation to SE | |
PDF 175 KB |
| 29 Jul 2019 | Strides JVin Hong Kong | |
PDF 158 KB |
| 29 Jul 2019 | Strides Board Meeting Outcome | |
PDF 3.18 MB |
| 29 Jul 2019 | Strides Outcome of the BM Interim Dividend | |
PDF 57 KB |
| 29 Jul 2019 | SPSL Earnings Call Intimation | |
PDF 175 KB |
| 23 Jul 2019 | SE Intimation | |
PDF 1.7 MB |
| 23 Jul 2019 | EIR from USFDA on continued GMP status for the flagship facility in Bangalore | |
PDF 132 KB |
| 20 Jul 2019 | Strides announces successful completion of US FDA inspection at its flagship facility in Bangalore | |
PDF 217 KB |
| 17 Jul 2019 | Clarification on the Article appeared in Economic Times on July 17, 2019 | |
PDF 333 KB |
| 10 Jul 2019 | SE Intimation | |
PDF 1.72 MB |
| 10 Jul 2019 | SE Intimation | |
PDF 1.80 MB |
| 10 Jul 2019 | Update on “Strides announces final closure of Arrow transaction" | |
PDF 133 KB |
| 05 Jul 2019 | SE Intimation - Book closure intimation and Record date | |
PDF 49 KB |
| 05 Jul 2019 | SE Intimation - AGM Notice and Annual Report for FY 18-19 | |
PDF 4.13 MB |
| 02 Jul 2019 | Update relating to “USFDA classifies Strides Puducherry facility as Official Action Indicated (OAI)”. | |
PDF 129 KB |
| 01 Jul 2019 | Update on “Strides to exit its investment in Arrow for AUD 394 Million" | |
PDF 128 KB |
| 19 Jun 2019 | Intimation under Reg 39 (3) of LODR | |
PDF 308 KB |
| 10 Jun 2019 | SE Intimation | |
PDF 1.60 MB |
| 08 Jun 2019 | Disclosure of Related Party Transactions for the half year ended March 31, 2019 | |
PDF 285 KB |
| 10 May 2019 | Audited Financial Results | |
PDF 2.2 MB |
| 10 May 2019 | Declaration of Final Dividend | |
PDF 117 KB |
| 10 May 2019 | SPSL Earnings Call Intimation | |
PDF 175 KB |
| 07 May 2019 | SE Intimation | |
PDF 1.7 MB |
| 06 May 2019 | USFDA classifies Strides Puducherry facility as Official Action Initiated (OAI) | |
PDF 146 KB |
| 03 May 2019 | Vivimed Life Sciences Private Limited (VLSPL) issues voluntary recall of 19 lots of Losartan Pottasium Tablets in USA due to detection of trace amount of N-Nitriso-N-methyl-4-aminobutyric acid (NMBA) impurity. These lots were manufactured at VLSPL's Alathur facility prior to acquisition by Strides | |
PDF 535 KB |
| 12 Apr 2019 | SE Intimation | |
PDF 183 KB |
| 05 Apr 2019 | SE Intimation | |
PDF 841 KB |
| 05 Apr 2019 | Intimation under Reg 39 (3) of LODR | |
PDF 812 KB |
| 04 Apr 2019 | Strides pharma intimation on window closure | |
PDF 89 KB |
| 03 Apr 2019 | SE Intimation | |
PDF 250 KB |
| 02 Apr 2019 | Receipt of Establishment Inspection Report (EIR) from US FDA for Singapore facility | |
PDF 997 KB |
| 02 Apr 2019 | Strides to launch Potassium Chloride Extended-Release Tablets in the US market | |
PDF 997 KB |
| 01 Apr 2019 | Amendment to the Code of Practices and Procedures for Fair Disclosure of Unpublished Price Sensitive Information | |
PDF 350 KB |
| 29 Mar 2019 | SE Intimation | |
PDF 1.6 MB |
| 27 Mar 2019 | SE Intimation | |
PDF 302 KB |
| 27 Mar 2019 | SE Intimation Lachhman Dass | |
PDF 280 KB |
| 27 Mar 2019 | USFDA approval for its greenfield oral dosage facility in Singapore | |
PDF 170 KB |
| 27 Mar 2019 | Intimation under Reg 39 (3) of LODR | |
PDF 290 KB |
| 19 Mar 2019 | SE Intimation | |
PDF 334 KB |
| 19 Mar 2019 | Intimation under Reg 39 (3) of LODR | |
PDF 322 KB |
| 18 Mar 2019 | SE Intimation | |
PDF 1.2 MB |
| 18 Mar 2019 | SE Intimation - Lata Kapoor | |
PDF 1.8 MB |
| 15 Mar 2019 | SE Intimation 2 | |
PDF 927 KB |
| 15 Mar 2019 | SE Intimation | |
PDF 312 KB |
| 08 Mar 2019 | SE Intimation | |
PDF 227 KB |
| 05 Mar 2019 | SE Intimation | |
PDF 1.7 MB |
| 22 Feb 2019 | SE Intimation | |
PDF 208 KB |
| 20 Feb 2019 | SE Intimation | |
PDF 1.1 MB |
| 20 Feb 2019 | USFDA approval for Ethosuximide Softgel Capsules | |
PDF 187 KB |
| 20 Feb 2019 | Intimation under Reg 39 (3) of LODR | |
PDF 1.02 MB |
| 13 Feb 2019 | USFDA approval for Triamcinolone Acetonide Cream | |
PDF 181 KB |
| 06 Feb 2019 | EIR from USFDA on continued GMP status for the flagship facility in Bangalore | |
PDF 177 KB |
| 04 Feb 2019 | SE Intimation | |
PDF 302 KB |
| 29 Jan 2019 | Outcome of Board meeting | |
PDF 2.03 MB |
| 29 Jan 2019 | Strides to exit its investment in Arrow | |
PDF 328 KB |
| 29 Jan 2019 | Strides to acquire 80% stake in Pharmapar Inc. | |
PDF 329 KB |
| 29 Jan 2019 | Strides to acquire 100% stake in Vensun Pharmaceuticals, Inc | |
PDF 326 KB |
| 29 Jan 2019 | SPSL Earnings Call Intimation | |
PDF 98 KB |
| 25 Jan 2019 | Strides to convert its 50:50 JV with Vivimed to 100% ownership | |
PDF 371 KB |
| 24 Jan 2019 | SE Intimation | |
PDF 235 KB |
| 22 Jan 2019 | SE Intimation | |
PDF 377 KB |
| 17 Jan 2019 | SE Intimation | |
PDF 253 KB |
| 03 Jan 2019 | SE Intimation - Rashmi Vyas | |
PDF 590 KB |
| 03 Jan 2019 | SE Intimation - Nitha Shah | |
PDF 366 KB |
| Date | Title | Report |
|---|
| 18 Dec 2018 | Intimation under Reg 39 (3) of LODR | |
PDF 1.79 MB |
| 14 Dec 2018 | Intimation under Reg 39 (3) of LODR | |
PDF 865 KB |